Psyence Biomedical (PBM) announced that its Board of Directors has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions. The Board’s decision followed a thorough and strategic review of the Company’s financial position, capital structure, prevailing market conditions, and Nasdaq listing considerations. The Strategy is intended to protect shareholder value, and preserve capital to fund planned clinical and regulatory milestones. Under the approved framework, the Company may repurchase its Common Shares from time to time, subject to liquidity, valuation, regulatory, and market conditions. Any repurchases would be conducted in compliance with applicable securities laws, Nasdaq rules, and applicable corporate law requirements, and executed through an independent third-party broker.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBM:
- Psyence Biomedical Calls January 22, 2026 Shareholder Meeting to Vote on Financials, Board and Share Consolidation
- Psyence Biomedical announces milestone in natural ibogaine HCl production
- Psyence Biomedical appoints Graham Patrick to board of directors
- Psyence Biomedical announces approval for use of PsyLab’s psilocybin product
- Psyence Biomedical CEO says 2025 was a ‘turning point’ for company